421 related articles for article (PubMed ID: 30582225)
1. Ectopic expression of PLC-β2 in non-invasive breast tumor cells plays a protective role against malignant progression and is correlated with the deregulation of miR-146a.
Bertagnolo V; Grassilli S; Volinia S; Al-Qassab Y; Brugnoli F; Vezzali F; Lambertini E; Palomba M; Piubello Q; Orvieto E; Natali C; Piva R; Croce CM; Capitani S
Mol Carcinog; 2019 May; 58(5):708-721. PubMed ID: 30582225
[TBL] [Abstract][Full Text] [Related]
2. Protective role of all-trans retinoic acid (ATRA) against hypoxia-induced malignant potential of non-invasive breast tumor derived cells.
Al-Qassab Y; Grassilli S; Brugnoli F; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2018 Nov; 18(1):1194. PubMed ID: 30497437
[TBL] [Abstract][Full Text] [Related]
3. Role of deregulated microRNAs in breast cancer progression using FFPE tissue.
Chen L; Li Y; Fu Y; Peng J; Mo MH; Stamatakos M; Teal CB; Brem RF; Stojadinovic A; Grinkemeyer M; McCaffrey TA; Man YG; Fu SW
PLoS One; 2013; 8(1):e54213. PubMed ID: 23372687
[TBL] [Abstract][Full Text] [Related]
4. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study.
Soon PS; Provan PJ; Kim E; Pathmanathan N; Graham D; Clarke CL; Balleine RL
Clin Exp Metastasis; 2018 Feb; 35(1-2):3-13. PubMed ID: 29214365
[TBL] [Abstract][Full Text] [Related]
5. PLC-β2 is modulated by low oxygen availability in breast tumor cells and plays a phenotype dependent role in their hypoxia-related malignant potential.
Brugnoli F; Grassilli S; Al-Qassab Y; Capitani S; Bertagnolo V
Mol Carcinog; 2016 Dec; 55(12):2210-2221. PubMed ID: 26785288
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
[TBL] [Abstract][Full Text] [Related]
7. Comparable cancer-relevant mutation profiles in synchronous ductal carcinoma in situ and invasive breast cancer.
Bergholtz H; Kumar S; Wärnberg F; Lüders T; Kristensen V; Sørlie T
Cancer Rep (Hoboken); 2020 Jun; 3(3):e1248. PubMed ID: 32671987
[TBL] [Abstract][Full Text] [Related]
8. miR-106b-5p and miR-17-5p could predict recurrence and progression in breast ductal carcinoma in situ based on the transforming growth factor-beta pathway.
Lee J; Kim HE; Song YS; Cho EY; Lee A
Breast Cancer Res Treat; 2019 Jul; 176(1):119-130. PubMed ID: 30989460
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin.
Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P
J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031
[TBL] [Abstract][Full Text] [Related]
10. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
12. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma
Lo PK; Zhang Y; Yao Y; Wolfson B; Yu J; Han SY; Duru N; Zhou Q
J Biol Chem; 2017 Jul; 292(27):11466-11484. PubMed ID: 28512126
[TBL] [Abstract][Full Text] [Related]
14. PIK3CA mutations in ductal carcinoma in situ and adjacent invasive breast cancer.
Agahozo MC; Sieuwerts AM; Doebar SC; Verhoef EI; Beaufort CM; Ruigrok-Ritstier K; de Weerd V; Sleddens HFBM; Dinjens WNM; Martens JWM; van Deurzen CHM
Endocr Relat Cancer; 2019 May; 26(5):471-482. PubMed ID: 30844755
[TBL] [Abstract][Full Text] [Related]
15. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB
BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211
[TBL] [Abstract][Full Text] [Related]
16. Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer.
Lee S; Stewart S; Nagtegaal I; Luo J; Wu Y; Colditz G; Medina D; Allred DC
Cancer Res; 2012 Sep; 72(17):4574-86. PubMed ID: 22751464
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvascularity.
Currie MJ; Beardsley BE; Harris GC; Gunningham SP; Dachs GU; Dijkstra B; Morrin HR; Wells JE; Robinson BA
Hum Pathol; 2013 Mar; 44(3):402-11. PubMed ID: 23036368
[TBL] [Abstract][Full Text] [Related]
18. Up-modulation of PLC-β2 reduces the number and malignancy of triple-negative breast tumor cells with a CD133
Brugnoli F; Grassilli S; Lanuti P; Marchisio M; Al-Qassab Y; Vezzali F; Capitani S; Bertagnolo V
BMC Cancer; 2017 Sep; 17(1):617. PubMed ID: 28870198
[TBL] [Abstract][Full Text] [Related]
19. Subtype-specific micro-RNA expression signatures in breast cancer progression.
Haakensen VD; Nygaard V; Greger L; Aure MR; Fromm B; Bukholm IR; Lüders T; Chin SF; Git A; Caldas C; Kristensen VN; Brazma A; Børresen-Dale AL; Hovig E; Helland Å
Int J Cancer; 2016 Sep; 139(5):1117-28. PubMed ID: 27082076
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation.
Li S; Meng H; Zhou F; Zhai L; Zhang L; Gu F; Fan Y; Lang R; Fu L; Gu L; Qi L
Pathol Res Pract; 2013 Mar; 209(3):179-83. PubMed ID: 23399321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
